Independent review of E2100 progression-free survival (PFS) with the addition of bevacizumab (B) to paclitaxel (P) as initial chemotherapy for metastatic breast cancer (MBC)

Autor:	Kathy D. Miller, B. J. Klencke, Meghna Samant, Nancy E. Davidson, Maura N. Dickler, Tamara Shenkier, Suman Bhattacharya, E. A. Perez, Julie Gralow, Melody A. Cobleigh
Rok vydání:	2008
Předmět:	Oncology Cancer Research Chemotherapy medicine.medical_specialty Bevacizumab business.industry medicine.medical_treatment medicine.disease Metastatic breast cancer chemistry.chemical_compound Paclitaxel chemistry Internal medicine Medicine Progression-free survival business medicine.drug
Zdroj:	Journal of Clinical Oncology. 26:1036-1036
ISSN:	1527-7755 0732-183X
Popis:	1036 Background: E2100 was an open-label, multi-center, randomized, Phase III trial comparing P to P+B as initial chemotherapy for MBC. The original analysis based on investigator-assessed progress...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::d9050871555395490494e9ef2e714073 https://doi.org/10.1200/jco.2008.26.15_suppl.1036 Zobrazit plný text záznamu